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Abstract: Heme oxygenase 1 (HO-1) up-regulation is recognized as a pivotal mechanism of cell
adaptation to stress. Under control of different transcription factors but with a prominent role
played by Nrf2, HO-1 induction is crucial also in nervous system response to damage. However,
several lines of evidence have highlighted that HO-1 expression is associated to neuronal damage
and neurodegeneration especially in Alzheimer’s and Parkinson’s diseases. In this review, we
summarize the current literature regarding the role of HO-1 in nervous system pointing out different
molecular mechanisms possibly responsible for HO-1 up-regulation in nervous system homeostasis
and neurodegeneration.
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1. Introduction
The heme degradation system was discovered in 1968 by Tenhunen and co-workers who described
a unique microsomal enzyme identified as heme oxygenase (HO) [1]. Subsequently, in 1986, Maines,
and, in 1993, Ewing described two different isoforms of HO of 32–36 kDa, namely HO-1 and HO-2,
expressed in mammalian cells [2,3] and later the third isoform (HO-3) was discovered in rats as a
pseudogene [4].
Through the biological activities of its metabolites, heme oxygenase exerts cytoprotection [5,6].
Indeed, HO degrades heme groups to carbon monoxide (CO), free ferrous iron (Fe2+) and
biliverdin [7,8]. From the activity of biliverdin reductase (BVR), biliverdin is converted to bilirubin
which is able to scavenge hydroxyl radicals, singlet oxygen and superoxide anions [9] and prevents
protein and lipid peroxidation [10,11], then exerting a strong antioxidant [12], anti-apoptotic [6]
and anti-inflammatory activity [13]. Moreover, through the modulation of soluble guanylyl
cyclase (sGC) and mitogen-activated protein kinase pathway (MAPK), CO exerts anti-apoptotic
and anti-inflammatory effects [5,6,14]. In addition, the release of free iron favors the synthesis of the
heavy chain of ferritin, which quenches free iron, and the activation of the membrane transporter
Fe-ATPase, which permits the cytosolic iron efflux, decreasing the intracellular free Fe2+ content and
preventing oxidative cell damage due to Fenton reaction [15,16].
The deregulation of HO system has been associated with the pathogenesis of Alzheimer’s
disease (AD), Parkinson’s disease (PD), multiple sclerosis, brain ageing, and its involvement has
been demonstrated in neurotoxicity and in the progression of neuroinflammation [17–19]. Among
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the different HO isoforms, HO-2 is constitutive and predominantly expressed in the brain [20].
Neurotoxicity is accentuated in HO-2 knock-out mice and the addition of exogenous bilirubin to
neuronal cultures exerts neuroprotective effects [21–23]. Thus, a cytoprotective role has been recognized
for HO-2 in neurons, especially against brain hypoxia, as reviewed in [24].
HO-1, instead, is the inducible form of heme oxygenase. It is present at low levels in most
mammalian tissues and is up-regulated by a number of oxidative stimuli as described below [7,25,26],
carrying out antioxidant and anti-inflammatory responses. In normal brain, HO-1 protein expression
is low and restricted to small groups of neurons and neuroglia [27]. On the contrary, HO-1 mRNA
is physiologically detectable with high levels in the hippocampus and cerebellum suggesting the
existence of a cellular reserve of HO-1 transcript quickly available for protein synthesis [20,28,29].
We focused on HO-1 as a key molecule involved in nervous system response to damage. Indeed,
the role played by HO-1 is highly complex and not completely understood. While it has been clearly
demonstrated that HO-1 activation in neurons is strongly protective against oxidative damage and cell
death [30,31], it is also evident that its up-regulation is associated to the late phase of neurodegeneration
and has been proposed as biomarker of AD [32]. Evidence related to the function of HO-1 in neuronal
cells as well as in astrocytes, oligodendrocytes and in microglia has been taken into consideration.
2. Molecular Mechanisms of HO-1 Induction
HO-1 gene (HMOX1) is located on chromosome 22q12. It has five exons, four introns and a
promoter region with one proximal and two or more distal enhancers [7]. The presence of different
binding sequences for many transcription factors such as Nrf2, NF-κB, Hypoxia-inducible factor 1
(HIF1), Activator Protein 1 (AP-1), Activator Protein 2 (AP-2), and metal-, stress- or cadmium-response
elements renders HO-1 the downstream target of different transduction pathways. Then, it is
responsive to many stimuli such as heavy metals, radiations, reactive oxygen species (ROS), modified
lipids, growth factors, and inflammatory cytokines [7,25,33]. As described for other tissues, Nrf2 is
recognized as a pivotal regulator of HO-1 induction also in brain and nervous system [34].
Nrf2 is a redox transcription factor involved in the regulation of the cellular redox state.
It is responsible for the activation of several antioxidants and phase I and II drug-metabolizing
enzymes [35–37]. In normal conditions, Nrf2 is retained into the cytoplasm by its negative regulator
Keap-1 which induces its ubiquitination and proteasomal degradation [38]. Under oxidative or
electrophilic stressors, Keap-1 is modified and Nrf2 moves into the nucleus where dimerizes with small
Maf proteins (sMafs), binds to the Antioxidant Response Elements (ARE) sequences and activates the
transcription of its target genes, among which HO-1 [39].
Thus, HO-1 expression is induced by many activators but only few negative regulators are
known, namely Keap-1, which acts reducing Nrf2 protein levels as explained, and Bach1 [40,41].
Working as a heme-binding protein, Bach1 in resting conditions dimerizes with sMafs and binds
to the ARE/Electrophile Responsive Element (EpRE) sequences preventing ARE-dependent gene
transcription. Under oxidative conditions or when the concentration of heme groups increases, Bach1
is modified, displaced from ARE sequences and degraded to proteasome, allowing Nrf2 to bind [42,43].
It is important to note that many stressing conditions, particularly oxidative stressors, favor the release
of heme groups from different proteins such as myoglobin, cytochromes, peroxidases, which induces
Bach1-dependent HO-1 activation as a mechanism of cell adaptation. The consequent generation of
biliverdin and bilirubin confers cytoprotection and the co-stimulation of ferritin and iron-transporters
prevents iron toxicity [44]. Conversely, it has been shown that HO-1 up-regulation, depending on its
intensity and duration, can increase tissue damage manly through heme-derived iron, which favors
oxidative stress in mitochondria and other compartments, as further explained below in this review.
Interestingly, at least two promoter polymorphisms have been hypothesized to influence HO-1
gene transcription, exerting a role in different human diseases [45]. Indeed, especially the (GT)n
dinucleotide length polymorphism and the single nucleotide polymorphism (SNP) (−413)TT have been
proved to reduce the efficiency of HO-1 transcription, increasing susceptibility to oxidative damage,
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as widely proved in different cardiovascular diseases [45]. Even though only few works have been
published with regard to neurodegeneration so far, it has been proved that GT sequences are highly
polymorphic in AD and PD subjects, but no correlation with a specific allele has been demonstrated [46].
Moreover, a correlation among the SNP (−413)TT and the development of AD has been pointed out in
subjects carrying also the tau (5′ of exon 1)AA polymorphism [47] or in combination with SNPs in liver
X receptor β (LXR β) such as (intron2)TT, (intron 5)AA and (intron 7)TT [48]. These results underline
the protective effect of HO-1 induction in preventing tau aggregation and oxysterols accumulation.
However, molecular mechanisms involved in HO-1 induction and, possibly, in its dysregulation
are still far from being completely understood, for instance as far as the modifications of the machinery
driving HO-1 transcription is concerned. In particular, it has been recently proved that Bach1
post-transcriptional modifications, especially ubiquitination, regulate its binding to HO-1 promoter
and are involved in the progression of AD [49]. In addition, in non-neuronal cell types, MafK
has been proved to be involved in HO-1 repression [50] and MafG in Nrf2 binding to ARE [51]
and post-transcriptional modifications such as ubiquitination, sumoylation or acetylation have been
postulated in the regulation of sMaf proteins as well [52]. Interestingly, in nervous system, MafK
and MafG genetic manipulations have been proved to be selectively involved in ARE-dependent
transcriptional abnormalities coincident with neuronal degeneration [53], even though, in this context,
the involvement of sMafs in the regulation of Bach1 as well as of Nrf2 binding to ARE is still unknown.
In addition, it seems important to consider the role played by microRNAs (miRs) in this
context. In fact, the so-called “redoximiRs” have been identified as crucially involved in different
pathological conditions, and different miRs have been proposed to regulate Nrf2, Bach1 and HO-1
in neuronal cells [54]. For instance, has-miR-590-3p contributes to the induction of HO-1, NAD(P)H
dehydrogenase [quinone] 1 (NQO1), Glutamate-Cysteine Ligase Modified subunit (GCLM), and
Glutamate-Cysteine Ligase Catalitic subunit (GCLC) conferring protection from oxidative damage [55].
The inhibition of miR-153 favors neuron survival during cerebral ischemia/reperfusion injury by
up-regulating Nrf2/HO-1 axis [56] and, in the same context, miR-424 enhances Nrf2 activity favoring
neuron survival [57,58]. Furthermore, we recently proved that miR-494 favors HO-1 up-regulation
independently on Bach1, in a neuroblastoma cell line exposed to oxidative stress [59]. Interestingly, it
has also been proved that miRs can be the targets of HO-1 activity, especially of HO-1 derived bilirubin,
CO and iron, which have been proved to modulate the expression of different miRs in astrocytes [60],
opening a new scenario in understanding HO-1 functions.
3. HO-1 Protective Effects in Nervous System
Oxidative stress is recognized as pivotal player in the pathogenesis of many neurodegenerative
conditions and it has been widely proved that HO-1 induction due both to genetic manipulation and
pharmacological treatments provides stress tolerance and neuroprotection. Indeed, in neuroblastoma
cell cultures HO-1 overexpression [30,61] or HO-1 up-regulation induced by plant-derived compounds
such as tetrahydroxystilbene glucoside [62] have been proved to be effective in reducing β-amyloid
induced oxidative stress and H2O2 dependent neuronal cell death.
The protective activity has been proved to be due to the generation of the end-products of HO-1
activity, as demonstrated by using ferulic acid which counteracts β-amyloid induced oxidative stress
through the increased generation of bilirubin and CO [63]. In this context, we recently showed
that HO-1 dependent endogenous generation of bilirubin is responsible for neuroblastoma cell
resistance to H2O2 but the efficiency of HO-1 induction decreases with neuronal differentiation,
underlining the idea that neuronal commitment can reduce HO-1 dependent adaptability [64]. Other
authors proved that CO inhibits the activation of AMP-activated protein kinase (AMPK) which is
implicated in the β-amyloid induced toxicity [65]. Similar results have been obtained considering
glutamate toxicity. Indeed, cerebellar granule cells from HO-1 overexpressing transgenic mice are
more resistant to glutamate and oxidative injury [31]. The protective role of HO-1 against oxidative
neuronal damage has been confirmed by experiment performed on animal models. Indeed, the
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intrathecal administration of cocaine- and amphetamine-regulated transcript (CART) neuropeptides
protects against neurodegeneration induced by β-amyloid microinjection in rat brain [66], and mouse
treatment with soybean-derived phytoalexin glyceollin prevents glutamate-induce neuronal damage
and improve cognitive function, in both cases through the up-regulation of Nrf2 and HO-1 [67].
In addition, in cortex and hippocampus from rats fed with Nrf2 activator tBHQ, the induction of HO-1
resulted protective against lead-induced oxidative damage [68].
The protective role of HO-1 up-regulation has been also proved as far as the PD is
concerned., The administration of Simvastatin, by up-regulating HO-1, exerts neuroprotective
effects improving antioxidant responses against 6-hydroxydopamine (6-OHDA)-induced PD
in animals [69]. Interestingly, in this context, it has been proved that the neuroprotectant
2′,3′-dihydroxy-4′,6′-dimethoxychalcone (DDC), by up-regulating Nrf2/HO-1 in glial cells, is able to
protect dopaminergic neurons against 6-OHDA-induced death, through the crucial contribution of
cell-to-cell transmission of CO [70]. Moreover, HO-1 can exert cytoprotection favoring proteasomal
degradation of α-synuclein and tau which has been proved to reduce the accumulation of toxic protein
aggregates in PD or AD [44,71]. Indeed, the reduction of proteasome activity is involved in the
formation of protein aggregates and contributes to the pathogenesis of various neurodegenerative
conditions [72]. In human neuroblastoma M17 cells, HO-1 overexpression promotes α-synuclein
proteasomal degradation through the generation of iron and CO, and independently on the
direct HO-1/α-synuclein interaction or on other non-enzymatic functions of HO-1 [73]. In the
same experimental model, the overexpression of HO-1 strongly reduces tau protein levels, by
downregulating ERK pathway [61].
Furthermore, the neuroprotective action of HO-1 may be due not only to its antioxidant
and anti-inflammatory activity but also to the enhancement of neurotrophic factor generation.
Adenovirus-induced HO-1 overexpression in substantia nigra up-regulates Brain-derived neurotrophic
factor (BDNF) and Glial cell-derived neurotrophic factor (GDNF) production in dopaminergic neurons
and glia, respectively [74,75]. In addition, the involvement of HO-1 downstream products in the
modulation of BDNF and GDNF expression in neurons and astrocytes has been demonstrated.
Indeed, low concentrations of free-form bilirubin promote GDNF or BDNF induction through the
activation of MEK, Akt and NF-κB pathways [76], and CO increases the expression of neurotrophic
factors via sGC-PKG-dependent pathway [75]. More recently, HO-1 role in favoring the release
of neurotrophic factors has been confirmed in mice subjected to stroke that show better recovery
activating BDNF-PI3K/Akt signaling in HO-1 overexpressing hippocampi [77]. Interestingly, it has
been recently demonstrated that resveratrol exerts protective activity against LPS-induced cytotoxicity
in oligodendrocytes restoring BDNF, GDNF and TGF-β generation, through the activation of Nrf2 and
HO-1, highlighting the existence of a HO-1 dependent glioprotective pathway [78].
HO-1 induction has also been proved to be involved in brain defense after ischemia. Indeed,
transgenic mice overexpressing HO-1 in neurons exhibit low levels of lipid peroxidation end-products,
and enhanced expression of the anti-apoptotic protein bcl-2 after cerebral ischemia [79]. In addition,
animal exposure to pterostilbene prevents ischemic brain damage in newborns through the
Nrf2-dependent induction of HO-1 [80], and, with the same biological meaning, the protective effect of
ischemic preconditioning is abolished in HO-1 gene deleted mice [81].
Moreover, HO-1 up-regulation plays a protective role against traumatic brain injury (TBI) and
hemorrhage. In fact, HO-1 expression in glial cells exerts neuroprotection in animal models of TBI [82].
In a mice model of selective HO-1 overexpression in astrocytes, a significant neuroprotection after
acute intracerebral hemorrhage has been proved [83,84] and, in the same context, systemic hemin
administration reduces blood brain barrier (BBB) damage and improves neurological recovery [85].
Furthermore, animal treatments aiming at HO-1 up-regulation, through the modulation of Nrf2 [86,87]
or PPARα [88], confirm HO-1 induction as protective response against post-hemorrhagic neuronal
dysfunctions. However, it is important to note that HO-1 up-regulation after brain hemorrhage seems
to follow a specific time course, with the early events that can be protective against oxidative stress,
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whereas late stage overexpression may result in dysfunctions and toxicity [89]. In addition, it has
recently been highlighted that HO-1 overexpression in microglia is necessary to attenuate neuronal cell
death and maintain cognitive functions in a mouse model of subarachnoid hemorrhage (SAH) [90].
Different studies on microglial cells showed that HO-1 up-regulation, mainly due to Nrf2
activation, has a strong anti-inflammatory effect. This has been proved both in cell cultures and
in animal models treated with different natural compounds able to activate Nrf2/HO-1 reducing
LPS-induced pro-inflammatory activation [91–93] and also reducing oxidative damage [94,95].
Moreover, HO-1 activity seems to play an important role against demyelination. Indeed, in an
animal model of cuprizone-induced demyelination, the administration of the flavonoid myricetin
improves motor dysfunction through the up-regulation of Nrf2 and HO-1 [96]. Furthermore,
in experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, the
expression of HO-1 is related to the pathological outcome. Indeed, HO-1 knockout mice show enhanced
demyelination, paralysis and mortality. Importantly, the induction of HO-1 obtained with colbalt
protoporphyrin IX (CoPPIX) [97], erythropoietin [98], or sulforaphane [99] modulates autoimmune
neuroinflammation and is able, also in mice with previously established EAE, to revert paralysis
leading to disease regression. However, it is important to note that opposite evidence has been
published pointing out that the efficacy of epigallocatechin-3-gallate and glatiramer acetate in the
therapy of EAE is in part due to the inhibition of HO-1 [100].
Interestingly, in a mouse model of Guillain-Barré syndrome (GBS), the treatment with dimethyl
fumarate strongly prevented autoimmune neuritis favoring macrophages M2 polarization through the
up-regulation of Nrf2 and HO-1 [101].
Finally, an important role of HO-1 in reducing neuropathic pain has been recently pointed out,
showing that HO-1 up-regulation could elicit potent analgesic effects in part due to the inhibition of
spinal microglia activation, as shown in a mouse model of peripheral nerve injury [102] or favoring
the antinociceptive effect of morphine in diabetic animals [103]. It has been also shown that the HO-1
dependent reduction of neuropathic pain is due to the specific modulation of MAPKs and Nrf2 and
the reduction of oxidative stress and neuroinflammation in prefrontal cortex and hypothalamus [104].
4. HO-1 Up-Regulation in Neurodegeneration
In the previous paragraph, we focused on pro-surviving effects elicited by HO-1 in nervous system.
However, HO-1 up-regulation has been widely associated with neuronal damage and degeneration as
well [105].
It has been hypothesized that HO-1 expression increases with ageing in human normal brain,
as the immunoreactivity for HO-1 progressively increases between 3 and 84 years of age both in
neurons and neuroglia and in cerebral cortex and hippocampus [106]. However, other studies showed
that in non-demented subjects, HO-1 immunoreactivity in neurons and in the temporal cortex is
not detectable [107] and HO-1 positivity is limited to normal substantia nigra pars compacta [108].
These results led to the hypothesis that during normal ageing, HO-1 can be up-regulated in specific
neuronal populations particularly susceptible to oxidative stress as an adaptive defense mechanism.
In this context, we previously showed an age-dependent up-regulation of HO-1 in rat liver tissue,
followed by an impairment of HO-1 induction in aged animals [109]. It seems important to note
that the neuroprotective effect of HO-1 induction is mainly due to the Nrf2-dependent activation,
as widely discussed earlier in this review. In ageing as well, for instance, there is evidence that
the Nrf2-dependent HO-1 up-regulation due to the treatment with flavonoids or carotenoids is
protective against galactose-induced ageing-like neurodegeneration [110,111] and that voluntary
running, through the up-regulation of HO-1, improves age-related cognitive decline in rats [112]. The
role played by Nrf2 in ageing and neurodegenerative diseases has been widely reviewed elsewhere and
there is a general agreement on the fact that in older organisms there is a decline of Nrf2 activity [113].
However, it remains well established that HO-1 is overexpressed in the brains of patients with AD,
mainly in the hippocampus and cerebral cortex, and co-localizes to neurons, neurofibrillary tangles,
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GFAP-positive astrocytes, choroid plexus epithelial cells, ependyma, corpora amylacea and senile
plaques [107,114]. Furthermore, HO-1 is strongly expressed in nigral astroglia and in dopaminergic
neuronal Lewy bodies in PD [108]. Moreover, as already mentioned, during acute brain damage and
hemorrhage, in which HO-1 up-regulation is mainly associated with tissue protection, HO-1 can be
subjected to protracted up-regulation which becomes dangerous for the tissue [89].
It has been postulated that HO-1 up-regulation in glial compartment may promote bioenergetics
failure, pro-toxin bioactivation, macroautophagy and corpora amylacea formation, by affecting iron
metabolism and mitochondrial activity, as reviewed in [44]. Indeed, transferrin receptor-independent
accumulation of iron and mitochondrial electron transport (complex I) deficits may be promoted
by the enhanced glial HO-1 activity [115–118]. In addition, the redox-active glial iron mediates
bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to the dopaminergic toxin
1-methyl-4-phenylpyridine (MPP+), despite the inactivation of monoamine oxidases [119] and that the
selective overexpression of HO-1 in astrocytes of transgenic mice induces parkinsonian features [120].
In addition, the therapeutic effect of targeted inhibition of glial HO-1 has been proved both in cell
cultures and in transgenic mouse model of AD [121].
However, it is important to report that opposite results have been recently published, proving
that HO-1 up-regulation in astrocytic compartment is protective against neurodegeneration, as shown
by exposure to the HO-1 inducer CoPPIX which protects astrocytes from β-amyloid toxicity [122]
and that specific HO-1 induction in astrocytes may protect dopaminergic neurons preventing PD in
MPTP-treated mice [123]. Unfortunately, in these reports, no evidence of the signal pathway involved
in HO-1 induction is provided.
Furthermore, another important aspect strongly deregulated in glial compartment due to HO-1
overexpression is the homeostasis of cholesterol. Indeed, following transient transfection of human
HO-1 in rat astrocytes, total cholesterol content significantly decreases while oxysterols formation
increases [124]. In the same cells, the heme degradation products—iron and CO—stimulate cholesterol
efflux via activation of the liver-X receptor (LXR) [125]. It has been proved that, in normal ageing
brain, sterol homeostasis is maintained and slightly influenced by glial HO-1 expression which,
instead, increases in AD and stimulates cholesterol biosynthesis and oxysterol formation. In particular,
in the early phase of the disease, total cholesterol levels remain normal or diminished since glial
cholesterol efflux is also induced and exceeds its biosynthesis. Conversely, in late AD, the diffuse
neuronal degeneration impairs cholesterol efflux generating a strong increase in free cholesterol which
exacerbate β-amyloid deposition and neurodegeneration [44,126].
However, we believe that in this context it is important also to consider that HO-1 induction
due to genetic manipulation is likely to produce a strong imbalance in the whole HO-1 dependent
molecular pathway. For instance, deregulating the balance between HO-1 activity and iron quenching
activity, which is fundamental to prevent iron-dependent toxicity. The correlation between the protein
level of HO-1 and the cytoprotective or cytotoxic outcome was demonstrated years ago by using an
inducible HO-1 vector in fibroblasts, clearly proving that there is a threshold of HO-1 up-regulation
beyond which the generation of free iron becomes toxic [127].
In addition, it can be hypothesized that the neurotoxic effect of HO-1 induction may be consequent
to a Nrf2-independent activation. This has been demonstrated in the MPP+-induced parkinsonian
rat model, where Nrf2 downregulation and HO-1 up-regulation have been observed in association
with the loss of nigral dopaminergic neurons [128]. Instead, in a similar experimental model, the
Nrf2-dependent activation of HO-1 induced by gintonin [129] or gastrodin [130] is protective against
neurodegeneration. Interestingly, it has been reported that brain astrocytes exposed to high glucose
concentration undergo apoptosis through the activation of HO-1 dependent on NF-κB and AP-1 [131],
supporting the hypothesis of an Nrf2-independent neurotoxic HO-1 activation.
Finally, HO-1 has been proposed as systemic marker in early sporadic AD. Indeed, plasma
HO-1 protein levels are significantly decreased in patients with probable sporadic AD [132]. The
up-regulation of HO-1 in AD brain can be explained as a consequence of local oxidative stress. Instead,
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the mechanism responsible for the downregulation of HO-1 in the blood of AD patients remains
unclear, even though the existence of a HO-1 suppressor that inhibits HO-1 mRNA levels in the
lymphocytes in AD plasma has been proposed [32,133]. However, the results about HO-1 plasma
levels in patients with AD are controversial. Another study reports no changes in the serum level
of HO-1 in a big cohort of AD patients in comparison to normal elderly control samples, and also
reports the increased level of serum HO-1 in Parkinson patients, underlining the existence of different
mechanisms involved in the peripheral response to oxidative stress in the two diseases [134]. Moreover,
another study reports that in plasma of probable AD patients, both HO-1 and biliverdin reductase
(BVR) levels are increased as a consequence of the enhanced oxidative stress, and plasma BVR status,
more than HO-1, is proposed as potential biochemical marker for the prediction of AD at the earliest
stages of disease [135].
5. Conclusions
HO-1 up-regulation represents a powerful mechanism of cell adaptation to stress and its
antioxidant, anti-apoptotic and anti-inflammatory properties are mainly due to the biological activity
of its metabolic products. However, to obtain cytoprotection, HO-1 up-regulation needs to be followed
by a parallel activation of other enzymes such as biliverdin reductase which is crucial to guarantee
the generation of bilirubin from biliverdin or heavy chain of ferritin and iron transporters, since HO-1
derived free iron needs to be rapidly quenched.
It is conceivable that one of the factors involved in cytoprotective or cytotoxic outcome of
HO-1 up-regulation may be related to the signaling pathways involved in HO-1 induction. Indeed,
Nrf2-dependent activation of HO-1 is generally linked to a protective adaptation of neurons and
glial cells as well, while the Nrf2-independent activation of HO-1, which often involves AP-1 or
NF-κB, seems to exert neurotoxic effects. This is probably due to the ability of Nrf2 to also drive
the transcription of other antioxidant and protective genes and proteins involved in iron quenching,
chelation and transport.
To be protective, HO-1 activity needs to be maintained in a well-defined molecular pathway
which involves the generation of heme, its degradation and the ultimate conversion of HO-1-derived
products in non-toxic and active compounds. The overall exacerbation of this protective mechanism
can increase cell resistance to many stressors, favoring the gain of an aggressive tumor phenotype [136],
but the untimely, prolonged or excessive activation of HO-1 can easily produce a deleterious cytopathic
effect. In the nervous system, this mechanism becomes even more complex due to cell–cell interactions,
characteristic of brain tissue. In fact, the dysregulation of heme degradation pathway through the
alteration of iron metabolism and the mitochondrial impairment leads to neurodegeneration not only
when it occurs in neurons but also, typically, when it occurs in glial cells. The main concepts have been
summarized in Figures 1 and 2 and Table 1.
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Table 1. Effects of HO-1 induction in neurological diseases.
Disease Effect Summary Experimental Model Refs
AD
Neuroprotection
HO-1 overexpression reduces tau expression and inactivates MAPK cascade. NB cells [61]
HO-1 reduces β-amyloid toxicity through CO generation and AMPK inhibition. SH-SY5Y NB cells and rat primaryneurons [65]
HO-1 exerts cytoprotection promoting tau proteasomal degradation. M17 NB cells [44,71]
Tetrahydroxystilbene glucoside up-regulates HO-1 and increases neuronal survival. HT-22 cells exposed to Aβ [62]
CART neuropeptides up-regulate Nrf2/HO-1 axis favoring neuroprotection. AD rat model (Aβ injection in brain) [66]
Neurodegeneration
HO-1 is overexpressed in AD brains and co-localizes to neurons, astrocytes, choroid plexus epithelial
cells, ependyma, corpora amylacea, neurofibrillary tangles and senile plaques. [44,107,114]
Targeted suppression of glial HO-1 by using HO-1-inhibitors exerts neuroprotection. APPswe/PS1∆E9 transgenic mice, ratastrocytes overexpressing HO-1 [121]
Transient transfection of rat astroglia with human HO-1 cDNA, significantly decreases intracellular
cholesterol content and increases oxysterols levels. Primary neonatal rat astrocytes [124]
HO-1 overexpression and its byproducts stimulate cholesterol efflux via activation of liver-x-receptor. Primary neonatal rat astrocytes [125]
HO-1 overexpression in astroglia from AD brains promotes the oxidation of cholesterol to oxysterols. Primary neonatal rat astrocytes [44,126]
Plasma HO-1 protein levels are significantly decreased in patients with probable sporadic AD. Sporadic AD and MCI Patients [32,132]
The activity of the HO-1 suppressor α1-antitrypsin reduces HO-1 expression in AD plasma. Sporadic AD patients [133]
The HO-1/BVR status in plasma is a potential biomarker for the earliest stages of AD. Plasma from probable AD patients [135]
PD
Neuroprotection
HO-1 overexpression favors α-synuclein proteasomal degradation through the generation of iron
and CO. M17 NB cells [44,73]
HO-1 induction exerts a neuroprotective effect in dopaminergic neurons and glia through the
enhancement of neurotrophic factor generation. Parkinsonian rat model [73–75]
DDC prevents 6-OHDA-induced dopaminergic neuronal death through the up-regulation of glial
expression of HO-1.
C57BL/6N mice and primary
mesencephalic cultures from rat
embryos
[70]
ATR-I reduces the inflammatory response exerting by inducing HO-1. Male C57BL6/J mice, BV-2 mousemicroglial cells [92]
Vinyl sulfone activates Nrf2/HO-1 axis preventing neuroinflammation in microglia and in an animal
model of PD.
Male C57Bl/6 mice, BV-2 mouse
microglial cells [95]
Simvastatin up-regulates HO-1 and increases antioxidant responses in PD. Mice treated with 6-OHDA andSH-SY5Y cells exposed to 6-HODA [69]
Neurodegeneration
HO-1 is overexpressed in nigral astroglia and in dopaminergic neuronal Lewy bodies. [107,114]
HO-1 up-regulation is associated with the loss of nigral dopaminergic neurons. Wistar rats exposed to1-methyl-4-phenylpyridine (MPP+) [119]
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Table 1. Cont.
Disease Effect Summary Experimental Model Refs
Neuronal injury/
Neurotoxicity
Neuroprotection
HO-1 protects neurons against oxidative stress-induced injury. SN56 NB cells [30]
HO-1 overexpression protects from glutamate toxicity and H2O2-induced cell death. HO-1(−/−) Tg mice [31]
Glyceollin increases MAPK/Nrf2/HO-1 pathway and protects against glutamate-induced toxicity. HT22 cells [67]
Ferulic acid mediates neuroprotection through HO-1 up-regulation. SH-SY5Y NB cells [63]
t-BHQ-mediated induction of Nrf2/HO-1 pathway protects against lead neurotoxicity. SH-SY5Y NB cells, cortex andhippocampus from rat [68]
HO-1-derived bilirubin protects neuronal cells from oxidative stress but neuronal differentiation
decreases HO-1 induction. SH-SY5Y NB cells [64]
Quercetin increases Nrf2/HO-1 favoring neuroprotection against galactose-induced damage. D-galactose treated mice [110]
Neurodegeneration
Lycopene reduces neuroinflammation and improves cognitive functions in a model of
ageing-like neurodegeneration. D-galactose treated mice [111]
Glial HO-1 up-regulation promotes abnormal patterns of iron deposition and mitochondrial
insufficiency in different human neurodegenerative disorders.
Rat primary astrocytes and Tg mice
over-expressing HO-1 [114,116,117]
Inflammation
Neuroprotection
Resveratrol restores GDNF, BDNF and TGF-β production from oligodendrocytes by up-regulating
Nrf2/HO-1 axis.
Oligodendrocyte progenitor cells from
Wistar rats [78]
LPS-induced neuroinflammation is inhibited by Sophoraflavanone G through nuclear translocation of
Nrf2 and HO-1 upregulation. BV2 mouse microglial cells [91]
Tryptanthrin protects against LPS-induced inflammation via Nrf2/HO-1 antioxidant signaling. C57BL/6 mice, BV2 mousemicroglial cells [93]
Licochalcone E exerts anti-inflammatory and cytoprotective effects activating the Nrf2/HO-1 pathway. BV2, HEK293T and SH-SY5Y cells. [94]
HO-1 and its end-product CO have a protective effect against autoimmune neuroinflammation in
experimental autoimmune encephalomyelitis.
C57BL/6 and SJL/J mice, BV2 mouse
microglial cells [97]
EPO up-regulates endogenous HO-1 and represses immune and inflammatory responses in
experimental autoimmune encephalomyelitis. C57BL/6 mice [98]
Sulforaphane, by enhancing Nrf2/HO-1 activity, antagonizes autoimmune inflammation and inhibits
EAE development and severity. C57BL/6 mice [99]
Myricetin improves motor functions and reduces demyelination in vivo. Cuprizone-treated mice [96]
Neuronal damage Up-regulation of HO-1 contributes to diminish the neuroprotective effects of epigallocatechin-3-gallatein experimental autoimmune encephalomyelitis model. C57BL/6 mice [100]
Int. J. Mol. Sci. 2018, 19, 2260 11 of 20
Table 1. Cont.
Disease Effect Summary Experimental Model Refs
Ischemia Neuroprotection
HO-1 overexpression in hippocampus protects against cerebral I/R activating the
BDNF–TrkB–PI3K/Akt signaling pathway. Sprague-Dawley rats [77]
HO-1-mediated neuroprotection is related to enhanced expression of bcl-2, inhibition of nuclear
localization of p53 and decreased levels of lipid peroxidation end-products. HO-1 overexpressing mice [79]
HO-1 is required for ischemic preconditioning-induced neuroprotection against brain ischemia. HO-1 (−/−) Tg mice [81]
Pterostilbene administration prevents ischemic brain injury in newborns. Rat model of neonatal ischemic damage [80]
Traumatic brain
injury (TBI) Neuroprotection A prolonged glial induction of HO-1 exerts neuroprotection in animal models of traumatic brain injury. Sprague-Dawley rats [82]
Hemorrhage
Neuroprotection
Selective HO-1 overexpression in astrocytes exerts neuroprotection after intracerebral hemorrhage. HO-1 overexpressing mice [83,84]
Hemin administration reduces BBB damage and improves neurological outcome in experimental models
of traumatic and ischemic CNS injury. Swiss-Webster mice [85]
Nrf2/HO-1 up-regulation mediated by t-BHQ administration decreases the development of early brain
injury in a subarachnoid hemorrhage model. Sprague-Dawley rats [86]
Nrf2/HO-1 activation mediated by nicotinamide mononucleotide treatment induces neuroprotection
after intracerebral hemorrhage. CD1 mice [87]
Fenofibrate reduces neuronal damage of ICH rat brain by increasing HO-1 expression level and
decreasing NF-κB expression in PPARα-dependent manner.
ICH rat model, LN-18 glioblastoma
cells, rat brain astrocytes [88]
HO-1 overexpression and CO generation are necessary to reduce neuronal injury and cognitive
dysfunction in a mouse model of subarachnoid hemorrhage. SAH stroke murine model. [90]
Neuroprotection/
Neuronal damage
The early up-regulation of HO-1 has a protective role against oxidative stress, whereas late stage
overexpression may result in dysfunctions and toxicity in intracerebral hemorrhage. Sprague–Dawley rats [89]
Neuropatic pain Neuroprotection
HO-1 up-regulation exerts analgesic effects against neuropathic pain inhibiting spinal
microglia activation.
Mouse model of L5 spinal
nerve ligation [102]
HO-1 induction enhances the antinociceptive effects of morphine via inhibition of microglia activation in
painful STZ-induced diabetic neuropathy. STZ-treated C57BL/6J mice [103]
Guillain-Barré
syndrome (GBS) Neuroprotection
In a mouse model of GBS, treatment with dimethyl fumarate favors macrophages M2 polarization
through the up-regulation of Nrf2 and HO-1, preventing inflammation. Lewis rats [101]
Abbreviations used in the table: 6-OHDA, 6-hydroxydopamine; AD, Alzheimer’s Disease; Akt, serine/threonine kinase; AMPK, AMP-activated protein kinase; ATR-I, atractylenolide-I;
Bcl2, Anti-apoptotic factor B-cell lymphoma 2; BBB, blood brain barrier; BDNF, Brain-derived neurotrophic factor; BVR, biliverdin reductase; CART, cocaine- and amphetamine-regulated
transcript; CNS, Central Nervous System; CO, carbon monoxide; DDC, 2′,3′-dihydroxy-4′,6′-dimethoxychalcone; EAE, experimental autoimmune encephalomyelitis; EPO, Erythropoietin;
GBS, Guillain-Barré syndrome; HO-1, heme oxygenase-1; I/R, ischemia/reperfusion; ICH, intracerebral hemorrhage; LPS, lipopolysaccharide; MAPK, Mitogen Activated Protein Kinases;
MCI, Mild Cognitive Impairment; NB, neuroblastoma; NFκB, nuclear factor kappa light- chain-enhancer of activated B cells; Nrf2, nuclear factor erythroid-derived 2-like 2; PD, Parkinson’s
Disease; PI3K, phosphoinositide 3-kinase; PPARα, peroxisome proliferator-activated receptors alpha; SAH, subarachnoid hemorrhage; STZ, streptozotocin; t-BHQ, tert-butylhydroquinone;
TrkB, tropomyosinreceptorkinase B.
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Abbreviations
AD Alzheimer’s Disease
Akt Serine/threonine kinase
AMPK AMP-activated protein kinase
AP-1/2 Activator protein 1/2
ARE Antioxidant Response Elements
ATR-I Atractylenolide-I
Bach1 BTB domain and CNC homolog 1
BBB Blood brain barrier
Bcl2 Anti-apoptotic factor B-cell lymphoma 2
BDNF Brain-derived neurotrophic factor
BVR Biliverdin reductase
CART Cocaine- and amphetamine-regulated transcript
CNS Central Nervous System
CO Carbon monoxide
CoPPIX Cobalt protoporphyrin IX
DDC 2′,3′-dihydroxy-4′,6′-dimethoxychalcone
EAE Experimental autoimmune encephalomyelitis
EPO Erythropoietin
ERK Extracellular signal-regulated kinase
Fe2+ Free ferrous iron
GBS Guillain-Barré syndrome
GCLM Glutamate-Cysteine Ligase Modified subunit
GCLC Glutamate-Cysteine Ligase Catalitic subunit
GDNF Glial cell-derived neurotrophic factor
H2O2 Hydrogen peroxide
HIF1 Hypoxia-inducible factor 1
HMOX1 Heme oxygenase 1 gene
HO Heme oxygenase
I/R Ischemia/reperfusion
ICH Intracerebral hemorrhage
Keap1 Kelch-like ECH-associated protein 1
LPS Lipopolysaccharide
LXR Liver-x receptor
MAPK Mitogen Activated Protein Kinases
MCI Mild Cognitive Impairment
miRs microRNAs
MPP+ 1-methyl-4-phenylpyridine
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NB Neuroblastoma
NF-κB Nuclear factor kappa light- chain-enhancer of activated B cells
NOS Nitric oxide synthase
NQO1 NAD(P)H dehydrogenase [quinone] 1
Nrf2 Nuclear factor erythroid-derived 2-like 2
PD Parkinson’s Disease
PI3K Phosphoinositide 3-kinase
PPARα Peroxisome proliferator-activated receptors alpha
ROS Reactive oxygen species
SAH Subarachnoid hemorrhage
sGC Soluble guanylyl cyclase
STZ Streptozotocin
t-BHQ Tert-butylhydroquinone
TBI Traumatic brain injury
TrkB Tropomyosinreceptorkinase B
6-OHDA 6-hydroxydopamine
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